What is secondary parkinsonism, including its causes, clinical presentation, diagnostic work‑up, and management?

Secondary Parkinsonism: Overview

Secondary parkinsonism is an acquired parkinsonian syndrome caused by identifiable external factors—including medications, vascular lesions, structural brain abnormalities, metabolic disorders, toxins, infections, and immune-mediated conditions—rather than primary neurodegenerative protein accumulation. Unlike Parkinson's disease, secondary parkinsonism is potentially reversible when the underlying cause is identified and treated 1, 2.

Clinical Presentation

Motor Features

The motor presentation differs from idiopathic Parkinson's disease in several key ways:

• Rigidity, bradykinesia, and gait abnormalities predominate over rest tremor 1
• "Lower body parkinsonism" is characteristic, particularly in vascular parkinsonism and normal pressure hydrocephalus, with prominent gait disturbance affecting the legs more than upper extremities 3
• Bilateral presentation is more common than the asymmetric onset typical of Parkinson's disease 1
• Onset can be acute, subacute, or chronic depending on etiology 1

Associated Features

Look for these red flags that distinguish secondary from primary parkinsonism:

• Coexisting movement disorders: dystonia, chorea, or myoclonus 1
• Additional neurological signs: pyramidal signs, cerebellar findings, cognitive impairment, or cranial nerve abnormalities 1
• Poor or absent response to levodopa 2
• Rapid progression or stepwise deterioration (particularly in vascular causes) 2

Major Causes

1. Drug-Induced Parkinsonism (DIP)

The most common cause of secondary parkinsonism 4, 3:

• Neuroleptics/antipsychotics (typical > atypical agents) 5, 4
• Calcium channel blockers (particularly cinnarizine, flunarizine) 4
• Antiemetics (metoclopramide, prochlorperazine) 4
• Antidepressants (SSRIs can induce parkinsonism) 6
• Valproate, lithium 4

Critical pitfall: DIP is frequently overlooked because prescribing physicians lack awareness of causative medications 3. Always obtain a complete medication history including over-the-counter drugs.

2. Vascular Parkinsonism

Caused by cerebrovascular disease affecting basal ganglia or their connections 1, 4:

• Stepwise progression with temporal relationship to vascular events
• Lower body predominance with shuffling gait, freezing, postural instability
• Pyramidal signs often present (hyperreflexia, Babinski sign)
• Neuroimaging shows strategic lacunar infarcts, white matter disease, or larger territorial strokes 1

3. Normal Pressure Hydrocephalus (NPH)

A treatable cause presenting with the classic triad 3:

• Gait disturbance (magnetic gait, shuffling)
• Cognitive impairment
• Urinary incontinence

Neuroimaging: ventriculomegaly disproportionate to sulcal atrophy 1

4. Structural Lesions

• Space-occupying lesions: tumors, subdural hematomas 1, 4
• Traumatic brain injury: chronic traumatic encephalopathy 4
• Hydrocephalus (obstructive or communicating) 1

5. Metabolic Causes

• Acquired hepatocerebral degeneration (cirrhosis with portosystemic shunting) 1
• Basal ganglia calcifications: hypoparathyroidism, pseudohypoparathyroidism 7, 1
• Hypoxic-ischemic injury 1
• Wilson's disease (akinetic-rigid syndrome, "juvenile Parkinsonism") 8

6. Toxic Exposures

• Carbon monoxide 1, 4
• Manganese 1, 4
• Methanol, cyanide 1
• MPTP (illicit drug contaminant) 1, 4

7. Infectious/Immune Causes

• Post-encephalitic parkinsonism (historical: encephalitis lethargica; current: viral encephalitides) 9
• COVID-19 related (emerging recognition) 9
• Paraneoplastic syndromes 9
• Autoimmune: SLE, Sjögren syndrome 9
• Immune checkpoint inhibitor-induced (cancer immunotherapy) 9

Diagnostic Work-Up

Essential Neuroimaging

Brain MRI is mandatory to identify structural causes 1, 2:

• Vascular lesions: lacunar infarcts, white matter hyperintensities
• Hydrocephalus: ventricular enlargement
• Basal ganglia abnormalities: calcifications, T1 hyperintensity (manganese, hepatocerebral degeneration)
• Tumors or mass lesions
• Demyelination patterns (osmotic demyelination syndrome)

Laboratory Evaluation

Tailor based on clinical suspicion:

• Complete blood count, comprehensive metabolic panel
• Thyroid function (hypothyroidism can worsen parkinsonism)
• Calcium, phosphorus, parathyroid hormone (if calcifications present) 7
• Ceruloplasmin, 24-hour urinary copper (Wilson's disease if age <40) 8
• Liver function tests (hepatocerebral degeneration)
• Autoimmune panel if immune etiology suspected (ANA, anti-Ro/La, paraneoplastic antibodies) 9
• Infectious workup if indicated (HIV, syphilis, viral titers)

Medication Review

Systematically review all medications with attention to:

• Timing of symptom onset relative to drug initiation
• Dose escalations
• Recent additions of multiple agents

Functional Imaging (When Available)

• DaTscan (dopamine transporter imaging): Normal in DIP, vascular parkinsonism, and NPH; abnormal in neurodegenerative parkinsonism 2
• Helps distinguish secondary from neurodegenerative causes when diagnosis uncertain

Management Approach

Algorithm for Treatment

Step 1: Identify and Address Underlying Cause

• If drug-induced: Discontinue or substitute the offending agent. Improvement typically occurs within weeks to months, though may take up to 18 months 3. Caveat: Some patients may not fully recover despite drug withdrawal 2.

• If vascular: Aggressive vascular risk factor modification (blood pressure control, antiplatelet therapy, statin, diabetes management) to prevent progression 4

• If NPH: Refer for neurosurgical evaluation for ventriculoperitoneal shunt placement 3

• If metabolic: Correct the specific abnormality (calcium supplementation for hypoparathyroidism, chelation for Wilson's disease) 7, 8

• If structural lesion: Neurosurgical intervention if indicated (tumor resection, hematoma evacuation)

• If toxic: Remove exposure, supportive care, specific antidotes when available

• If immune/paraneoplastic: Immunotherapy (corticosteroids, IVIG, plasma exchange), treat underlying malignancy 9

Step 2: Symptomatic Treatment

Levodopa trial is warranted even in secondary parkinsonism, though response is typically poor to absent 2:

• Start levodopa/carbidopa 25/100 mg three times daily
• Titrate to 25/100 mg four times daily or higher if tolerated
• If no response after adequate trial (600-800 mg levodopa daily for 2-3 months), discontinue 2

Physical therapy is beneficial regardless of etiology 10:

• Gait training
• Balance exercises
• Strengthening programs
• Fall prevention strategies

Step 3: Monitor and Reassess

• Serial neuroimaging if vascular etiology to assess progression
• Repeat clinical assessment 3-6 months after intervention
• Adjust treatment based on response and evolution of symptoms

Key Clinical Pitfalls

1. Failing to obtain complete medication history: DIP is the most common and most overlooked cause 3

2. Assuming irreversibility: DIP and NPH are treatable; early recognition improves outcomes 3

3. Missing Wilson's disease in young patients: Always consider in parkinsonism onset before age 40, especially with psychiatric symptoms or liver disease 8

4. Overlooking hypocalcemia: Can present with parkinsonism and movement disorders; check calcium in all patients with basal ganglia calcifications 7

5. Attributing symptoms to "normal aging": Vascular parkinsonism and NPH are often dismissed as age-related decline 3

6. Not recognizing immune-mediated causes: Increasing recognition with checkpoint inhibitor use and post-viral syndromes 9